Company Overview and News

1
AVGR / Avinger, Inc. 10-K (Annual Report)

2018-03-30 sec.gov
Table of Contents
Upvote Downvote

 
BRIEF-Avinger To Settle Securities Class Actions For $5 Million

2018-03-21 reuters
* AVINGER INC - ENTERED INTO BINDING MEMORANDUM OF UNDERSTANDING TO SETTLE SECURITIES CLASS ACTIONS PENDING AGAINST CO, SEVERAL OF OFFICERS & DIRECTORS
Upvote Downvote

 
 
Avinger's (AVGR) CEO Jeff Soinski on Q4 2017 Results - Earnings Call Transcript

2018-03-20 seekingalpha
Good day, ladies and gentlemen, and welcome to the Q4 2017 Avinger Inc. Earnings Conference Call. At this time all participants are in a listen-only mode. Following managements prepared remarks, we will host a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, this conference call maybe recorded for replay purposes.
Upvote Downvote

 
 
AVGR / Avinger, Inc. null

2018-03-15 sec.gov
February 12, 2018 Via EDGAR
Upvote Downvote

 
AVGR / Avinger, Inc. null

2018-03-15 sec.gov
Ladenburg Thalmann & Co. Inc. 999 Vanderbilt Beach Road, Suite 200
Upvote Downvote

 
BRIEF-Avinger Provides Update On U.S. Intellectual Property Portfolio

2018-03-13 reuters
* AVINGER INC - ANNOUNCED 3 RECENT ADDITIONS TO U.S. INTELLECTUAL PROPERTY PORTFOLIO Source text for Eikon: Further company coverage:
Upvote Downvote

 
AVGR / Avinger, Inc. 8-K (Current Report)

2018-02-23 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 16, 2018     Avinger, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-36817   20-8873453 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

 
AVGR / Avinger, Inc. / Empery Asset Management, LP - AVINGER INC. (Passive Investment)

2018-02-21 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934   (Amendment No.   )*   Avinger Inc. (Name of Issuer)   Common Stock, $0.001 par value (Title of Class of Securities)   053734208 (CUSIP Number)   February 14, 2018 (Date of event which requires filing of this statement)     Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:   ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ Rule 13d-1(d)   (Page
Upvote Downvote

2
AVGR / Avinger, Inc. / Empery Asset Management, LP - AVINGER INC. (Passive Investment)

2018-02-21 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G     Under the Securities Exchange Act of 1934   (Amendment No.   )*   Avinger Inc. (Name of Issuer)   Common Stock, $0.001 par value (Title of Class of Securities)   053734208 (CUSIP Number)   February 14, 2018 (Date of event which requires filing of this statement)     Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:   ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ Rule 13d-1(d)   (Page
Upvote Downvote

 
AVGR / Avinger, Inc. / WADDELL & REED FINANCIAL INC - AVINGER, INC. (Passive Investment)

2018-02-16 sec.gov
AVINGER, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 6* Avinger, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 053734109 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this
Upvote Downvote

 
AVGR / Avinger, Inc. / WADDELL & REED FINANCIAL INC - AVINGER, INC. (Passive Investment)

2018-02-15 sec.gov
AVINGER, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 6* Avinger, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 053734109 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this
Upvote Downvote

 
AVGR / Avinger, Inc. 424B4 (Prospectus)

2018-02-15 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS INDEX TO UNAUDITED FINANCIAL STATEMENTS Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-222517 Registration No. 333-223023 Avinger, Inc. 17,979 Shares of Series B Convertible Preferred Stock (and 8,989,500 Shares of Common Stock Underlying the Series B Convertible Preferred Stock) Warrants to Purchase up to 17,979,000 Shares of Common Stock (and 17,979,000 Shares of Common Stock
Upvote Downvote

AVGR : Avinger Stock Analysis and Research Report

2017-11-10 - Asif

Avinger is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease, or PAD. Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The company's mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular platform, the only intravascular image-guided system available in this market. The company manufacture and sell a suite of products in the United States and select international markets. The company's current products include its Lightbox imaging console, as well as its Wildcat, Kittycat 2, and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion, or CTO, and Pantheris, its image-guided atherectomy ...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 053734109